CA-NEXON-AMERICA
12.5.2020 00:41:09 CEST | Business Wire | Press release
Prepare for a thrilling ride as free-to-play mobile kart racer, KartRider Rush+ , launches on iOS and Android devices on May 12. Buckle up to experience a robust set of tracks, innovative and diverse game modes and countless kart customization options that redefine the world of kart racing games.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200511005971/en/
The latest iteration of the insanely popular KartRider franchise, KartRider Rush+ features over 50 race tracks and 20 karts at launch delivering unmatched kart and character customization options, ranging from decals, plates, skins and more.
KartRider Rush + is built for bursts of gameplay on the go or longer durations played with fellow racers offering something for everyone with several modes including:
- Story Mode: Story Mode allows players to fully immerse themselves in the game, learning about character backstories and showcasing various game modes.
- Speed Race Mode: This mode challenges racers to compete against each other and use their drifting skills to earn EXP that can unlock more challenging tracks.
- Arcade Mode: Whether playing solo or in teams, players can enjoy additional gameplay options within Arcade Mode, such as Item Race, Infini-Boost and Lucci Runner.
- Ranked Mode: From Bronze to Living Legend, players can rank up tiers and earn rewards such as K-Coins to purchase a variety of items in the Shop.
- Time Trial: This mode is all about beating the clock to become the fastest racer.
For players looking to achieve ultimate racing prowess, KartRider Rush+ introduces a Mentorship System, which allows racers to team up with mentors to improve their skills or sign up as mentors to guide other players. All players participating in this system will receive mentorship perks and rewards. The Club System also makes it easy for racers to join forces and work together to complete challenges, daily activities and earn rewards.
Additionally, all players will be able to claim the pre-registration milestone rewards until May 25th, 2020. Pre-registration rewards include Skelemech Kart, Slugger Dao Character, Angel Wing Headset, Star Driftmoji and Love Candy Balloon added as a bonus item after reaching 5 million pre-registrations ahead of launch.
To celebrate the launch, KartRider Rush+ has partnered with iconic peripheral manufacturer, HyperX. As part of the partnership, KartRider Rush+ will host giveaways of HyperX gaming peripherals including the HyperX Cloud MIX™ headset and the HyperX ChargePlay Clutch™ designed for longer, more comfortable gaming sessions.
KartRider Rush+ will be available globally in multiple languages including English, Korean, Thai, and Traditional Chinese. Visit https://kartrush.nexon.com for the latest updates and information.
Social Media: Twitch / Facebook / Twitter / Instagram / YouTube
Press Assets:
About KartRider Rush+ https://kartrush.nexon.com
Based on the popular online gaming phenomenon, KartRider , KartRider Rush+ is a free-to-play kart racing mobile game delivering all the racing action of its namesake on iOS and Android devices. With gorgeous 3D graphics, KartRider Rush+ offers players robust tracks, karts and game modes, just like its online counterpart accommodating every level, from racing novice to drifting champion.
About Nexon America Inc. http://www.nexon.net/corporate/about-nexon/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200511005971/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom